Clinical Trials With
TheraSphere® YTTRIUM-90 GLASS MICROSPHERES

TheraSphere® is a liver cancer therapy that consists of millions of small glass microspheres (20 to 30 micrometers in diameter) containing radioactive Y90. The product is injected by a physician into the artery of the patients liver through a catheter, which allows the treatment to be delivered directly to the tumor via the blood flow.

EPOCH

Protocol TS-102 / NCT01483027
Evaluating yttrium-90 trans-arterial radioembolization (TheraSphere®) in patients with metastatic colorectal carcinoma of the liver who have failed first-line chemotherapy If you are a EPOCH Principal Investigator Login HereTo contact the Study Director Click Here

STOP-HCC

Protocol TS-103 / NCT01556490
Evaluating yttrium-90 trans-arterial radioembolization (TheraSphere®) in the treatment of patients with unresectable hepatocellular carcinoma (HCC)
 
If you are a STOP-HCC Principal Investigator Login HereTo contact the Study Director Click Here

YES-P

Protocol TS-104 / NCT01887717
Evaluating yttrium-90 trans-arterial radioembolization (TheraSphere®) versus the standard of care (sorafenib) for the treatment of advanced HCC with portal vein thrombosis If you are a YES-P Principal Investigator Login HereTo contact the Study Director Click Here

CAUTION - Investigational Device.
Limited by United States law to investigational use.